Effectiveness of Targeted Therapy in the Treatment of Triple-negative Breast Cancer and Comparison with Other Treatments

Inhalt:
Triple-negative breast cancer (TNBC) is one of the four clinical classifications of breast cancer, which refers to breast cancer with immunohistochemical results negative for progesterone receptor (PR), estrogen receptor (ER) and protooncogene Her-2. It is also known as the "king of breast cancers" because of its poor prognosis. The current treatment for triple-negative breast cancer includes chemotherapy, radiotherapy and surgery. By comparing the principles and side effects of these treatments with targeted therapies, we highlight the advantages of targeted therapies and provide better treatment options for triple negative breast cancer.